| Literature DB >> 30892182 |
Meera Tandan1, Rory O'Connor2, Karen Burns3,4, Helen Murphy3, Sarah Hennessy3, Fiona Roche3, Sheila Donlon3, Martin Cormican5,6, Akke Vellinga1,5.
Abstract
BackgroundLong-term care facilities (LTCFs) are important locations of antimicrobial consumption. Of particular concern is inappropriate prescribing of prophylactic antimicrobials. AimWe aimed to explore factors related to antimicrobial prophylaxis in LTCFs in Ireland. MethodsThe point prevalence surveys of Healthcare-Associated Infections in Long-Term Care Facilities (HALT) were performed in Ireland in May 2013 and 2016. Data were collected on facility (type and stewardship initiatives) and resident characteristics (age, sex, antimicrobial and indication) for those meeting the surveillance definition for a HAI and/or prescribed an antimicrobial. ResultsIn 2013, 9,318 residents (in 190 LTCFs) and in 2016, 10,044 residents (in 224 LTCFs) were included. Of the 10% of residents prescribed antimicrobials, 40% were on prophylaxis, most of which was to prevent urinary tract infection. The main prophylactic agents were: nitrofurantoin (39%) and trimethoprim (41%) for urinary tract (UT); macrolides (47%) for respiratory tract and macrolides and tetracycline (56%) for skin or wounds. More than 50% of the prophylaxis was prescribed in intellectual disability facilities and around 40% in nursing homes. Prophylaxis was recorded more often for females, residents living in LTCFs for more than 1 year and residents with a urinary catheter. No difference in prophylactic prescribing was observed when comparing LTCFs participating and not participating in both years. ConclusionsForty per cent of antimicrobial prescriptions in Irish LTCFs were prophylactic. This practice is not consistent with national antimicrobial prescribing guidelines. Addressing inappropriate prophylaxis prescribing in Irish LTCFs should be a key objective of antimicrobial stewardship initiatives.Entities:
Keywords: antimicrobial; long-term care facilities, HALT; prescribing; prophylaxis
Mesh:
Substances:
Year: 2019 PMID: 30892182 PMCID: PMC6425550 DOI: 10.2807/1560-7917.ES.2019.24.11.1800102
Source DB: PubMed Journal: Euro Surveill ISSN: 1025-496X
Comparison of prophylactic antimicrobial use by care types in HALT, Ireland 2013 and 2016
| LTCF types | HALT 2013 (n = 9,318) | HALT 2016 (n = 10,044) | p valuec | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of LTCFs | Residents | No of LTCFs | Residents | ||||||||||
| Total | AMa | Prophylactic AMb | Total | AMa | Prophylactic AMb | ||||||||
| n | % | n | % | n | % | n | % | ||||||
|
| |||||||||||||
| GNH | 58 | 2,881 | 314 | 10.9 | 120 | 38.2 | 54 | 2,725 | 235 | 8.6 | 104 | 44.3 | 0.18 |
| Mixed facility | 26 | 1,447 | 79 | 5.5 | 32 | 40.5 | 24 | 1,397 | 149 | 10.7 | 48 | 32.2 | 0.27 |
| IDF | 19 | 833 | 72 | 8.6 | 38 | 52.8 | 19 | 892 | 61 | 6.8 | 30 | 49.2 | 0.81 |
| Psychiatric | 7 | 200 | 10 | 5.0 | 4 | 40.0 | 7 | 173 | 10 | 5.8 | 5 | 50 | 0.65 |
| Palliative | 4 | 90 | 30 | 33.3 | 10 | 33.3 | 4 | 93 | 30 | 32.3 | 5 | 16.7 | 0.23 |
| Rehabilitation | 3 | 181 | 14 | 7.7 | 2 | 14.3 | 3 | 187 | 12 | 6.4 | 3 | 25.0 | 0.49 |
| Physical disability | 1 | 28 | 0 | NA | NA | NA | 1 | 13 | 0 | NA | NA | NA | NA |
| Others | 1 | 29 | 0 | NA | NA | NA | 7 | 177 | 19 | 10.7 | 11 | 57.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| GNH | 112 | 6,019 | 567 | 9.4 | 217 | 38.3 | 102 | 5,163 | 493 | 9.5 | 213 | 43.2 | 0.10 |
| Mixed facility | 32 | 1,571 | 165 | 10.5 | 56 | 33.9 | 46 | 2,499 | 250 | 10.0 | 106 | 42.4 | 0.08 |
| IDF | 24 | 1,060 | 106 | 10.0 | 54 | 50.9 | 31 | 1,251 | 102 | 8.2 | 55 | 53.9 | 0.66 |
| Psychiatric | 11 | 345 | 23 | 6.7 | 6 | 26.1 | 23 | 505 | 39 | 7.7 | 12 | 30.8 | 0.69 |
| Palliative | 4 | 89 | 31 | 34.8 | 10 | 32.3 | 7 | 134 | 44 | 32.8 | 9 | 20.5 | 0.24 |
| Rehabilitation | 3 | 139 | 14 | 10.1 | 2 | 14.3 | 5 | 245 | 22 | 8.9 | 5 | 22.7 | 0.53 |
| Physical disability | 2 | 46 | 0 | NA | NA | NA | 1 | 13 | 0 | NA | NA | NA | NA |
| Others | 2 | 49 | 7 | 14.3 | 5 | 71.4 | 9 | 234 | 31 | 13.2 | 17 | 54.8 | 0.42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AM: antimicrobials; GNH: general nursing homes; HALT: healthcare-associated infections in long-term care facilities; IDF: intellectual disability facility; LTCF: long-term care facility; NA: not applicable.
a Denominator for percentages is total residents in the facility.
b Denominator for percentages is AM.
c p value of difference in prophylaxis between 2013 and 2016.
Figure 1Proportion of residents prescribed prophylactic antimicrobials, by body site targeted, healthcare-associated infections in long-term care facilities point prevalence surveys, Ireland, 2013 and 2016, (A) in long-term care facilities which participated in both surveys (n=119) and (B) in long-term care facilities which participated in either survey (n = 190 in 2013 and n = 224 in 2016)
Figure 2Breakdown of antimicrobial agents’ prophylaxis by top three body sites, healthcare-associated infections in long-term care facilities point prevalence surveys, Ireland, 2013 and 2016
Multiple logistic regression analysis of prophylactic vs therapeutic antimicrobial prescribing in long-term care facilities, Ireland, Healthcare-Associated Infections in Long-Term Care Facilities (HALT) 2013 (n = 190 facilities) and 2016 (n = 224 facilities)
| Characteristics | Total | Prophylactic | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| n | % | OR (95% CI) | p value | |||
|
| < 85 years | 1,123 | 444 | 39.5 | ref | |
| > 85 years | 735 | 307 | 41.8 | 1.04 (0.8–1.3) | 0.37 | |
|
| Male | 696 | 243 | 34.9 | ref | |
| Female | 1,162 | 508 | 43.7 | 1.5 (1.2–1.8) | < 0.001 | |
|
| < 1 year | 604 | 175 | 28.9 | ref | |
| > 1 year | 1,254 | 576 | 45.9 | 1.4 (1.1–1.8) | 0.004 | |
|
| No | 1,445 | 649 | 44.9 | ref | |
| Yes | 413 | 102 | 24.7 | 0.5 (0.4–0.7) | < 0.001 | |
|
| No | 1,603 | 636 | 39.7 | ref | |
| Yes | 255 | 115 | 45.1 | 1.8 (1.4–2.5) | < 0.001 | |
|
| No | 1,802 | 747 | 41.5 | ref | |
| Yes | 56 | 4 | 7.1 | 0.2 (0.1–0.4) | < 0.001 | |
|
| No | 648 | 220 | 33.9 | ref | |
| Yes | 1,210 | 531 | 43.9 | 1.3 (1.1–1.7) | 0.005 | |
|
| No | 1,753 | 722 | 41.2 | ref | |
| Yes | 105 | 29 | 27.6 | 0.6 (0.4–1.0) | 0.03 | |
|
| GNH | 1,034 | 417 | 40.3 | ref | |
| IDF | 207 | 108 | 52.2 | 1.5 (1.1–2.2) | 0.007 | |
| Mixed | 410 | 162 | 39.5 | 1.0 (0.8–1.3) | 0.92 | |
| Other | 207 | 64 | 30.9 | 1.0 (0.7–1.4) | 0.87 | |
|
| 2013 only | 382 | 140 | 36.6 | ref | |
| 2016 only | 461 | 210 | 45.5 | 1.6 (1.2–2.1) | 0.002 | |
| Both (2013 and 2016) | 1,015 | 401 | 39.5 | 1.2 (1.0–1.6) | 0.09 | |
CI: confidence interval; GNH: general nursing home; HALT: healthcare-associated infections in long-term care facilities; IDF: intellectual disability facility; LOS: length of stay in long-term care facility; OR: odds ratio; ref: reference value.
a Indicates significant p value of < 0.05.
b Indicates hospital admission in last 3 months of survey.
Special cases in the studies (prophylactic and therapeutic antimicrobial prescribing)
| HALT-2013 | HALT- 2016 | ||||
|---|---|---|---|---|---|
| Resident | Antimicrobial | Prescribed for | Resident | Antimicrobial | Prescribed for |
| R13_1 | Doxycycline (P) | S/W | R16_1 | Azithromycin(P) | RT |
| Rifampicin (P) | S/W | Nitrofurantoin(P) | UT | ||
| R13_2 | Nitrofurantoin(P) | UT | R16_2 | Doxycycline(P) | S/W |
| Cephalexin(P) | UT | Nitrofurantoin(P) | UT | ||
| R13_3 | Mycostatin (P) | ENM | R16_3 | Nitrofurantoin(P) | UT |
| Co-amoxiclav (T) | RT | Doxycycline(P) | S/W | ||
| R13_4 | Erythromycin(P) | other | R16_4 | Cefalexin(P) | UT |
| Co-amoxiclav (T) | RT | Trimethoprim(P) | UT | ||
| R13_5 | Trimethoprim(P) | UT | R16_5 | Trimethoprim(P) | UT |
| Ciprofloxacin(T) | UT | Co-amoxiclav (T) | RT | ||
| R13_6 | Mycostatin(P) | ENM | R16_6 | Cefaclor(P) | S/W |
| Ciprofloxacin(T) | UT | Trimethoprim(T) | RT | ||
| R13_7 | Trimethoprim(P) | UT | R16_7 | Trimethoprim(P) | UT |
| Nitrofurantoin(P) | UT | Metronidazole (T) | Other | ||
| R13_8 | Nitrofurantoin(P) | UT | R16_8 | Cefixime(P) | RT |
| Trimethoprim(P) | UT | Azithromycin(P) | RT | ||
| R13_9 | Nitrofurantoin(P) | UT | R16_9 | Trimethoprim(P) | UT |
| Co-amoxiclav (P) | UT | Co-amoxiclav (T) | RT | ||
| Trimethoprim(P) | UT | Chloromycetin(T) | Eye | ||
| R13_10 | Trimethoprim(P) | UT | R16_10 | Doxycycline(P) | RT |
| Cefpodoxime(T) | RT | Cefixime(P) | RT | ||
| R13_11 | Trimethoprim(P) | UT | R16_11 | Cefixime(P) | RT |
| Ciprofloxacin(T) | UT | Doxycycline(P) | RT | ||
| R13_12 | Trimethoprim(P) | UT | R16_12 | Nitrofurantoin(P) | UT |
| Co-amoxiclav(T) | RT | Co-amoxiclav (T) | RT | ||
| R13_13 | Azithromycin(P) | RT | NA | ||
| Trimethoprim(T) | UT | ||||
ENM: ear, nose and mouth; HALT: healthcare-associated infections in long-term care facilities; P: resident is on prophylaxis for particular antimicrobials; RT: respiratory tract; S/W: skin or wounds; T: resident is on therapeutic treatment for particular antimicrobials; UT: urinary tract.
Every serial number (SN) represents a resident as R13_1, R13_2 and so on, R13 refers to residents in the 2013 survey and R16 is a resident in 2016.